| Literature DB >> 35784600 |
Amos Justinian Ngonzi1,2, Letus Laurian Muyaga1, Halfan Ngowo1, Naomi Urio1,2, John-Mary Vianney2, Dickson Wilson Lwetoijera1,2.
Abstract
Introduction: application of Insect Growth Regulator (IGR) such as pyriproxyfen has shown a promising result in controlling malaria transmitting mosquitoes through autodissemination technique. Novaluron that inhibits the chitin development at mosquito larval stage present a promising candidate IGR for rotation with pyriproxyfen to prevent a chance of resistance development. This study assessed the susceptibility of immature stages of Anopheles arabiensis, Anopheles gambiae and Anopheles funestus to novaluron.Entities:
Keywords: An. arabiensis; An. funestus; An. gambiae; Insect growth regulator; Tanzania; novaluron; susceptibility
Mesh:
Substances:
Year: 2022 PMID: 35784600 PMCID: PMC9206179 DOI: 10.11604/pamj.2022.41.273.33793
Source DB: PubMed Journal: Pan Afr Med J
Figure 1A) semi-field system used in experiments; B) chambers inside the semi-field; C) mosquito rearing insectary inside semi-field system
larval susceptibility of malaria vector species to novaluron
| Species | LC50 (mg/L) | 95%CI | LC90 (mg/L) | 95%CI | LC99 (mg/L) | 95%CI | Diagnostic Conc. (mg/L) |
|---|---|---|---|---|---|---|---|
|
| 0.018 | 0.016,0.020 | 0.332 | 0.168,0.496 | 2.001 | 1.986,3.206 | 4.002 |
|
| 0.026 | 0.027,0.038 | 0.546 | 0.374,0.719 | 2.013 | 1.997,4.491 | 4.026 |
|
| 0.032 | 0.021,0.03 | 1.000 | 0.467,1.535 | 5.580 | 4.687,8.496 | 11.160 |
Figure 2cumulative mortality percentage of: A) An. gambiae; B) An. arabiensis and C) An. funestus larvae when 1st instar larvae were treated with novaluron-chitin synthetic inhibitor
larvae mortality and their risk effects at different concentrations of novaluron
| Species | Conc. (mg/L) | Predicted mean (95%CI) | RR (95% CI) | P-value |
|---|---|---|---|---|
|
| 0.00 | 0.318 (0.149,0.675) | 1 | |
| 0.01 | 0.595 (0.280,1.265) | 0.518 (0.384,1.349) | 0.177 | |
| 0.05 | 1.293 (0.609,2.745) | 0.257 (0.384,0.668) | 0.504 | |
| 0.10 | 2.957 (1.391,6.284) | 1.084 (0.385,2.819) | 0.004 | |
| 2.00 | 7.786 (3.656,16.582) | 2.052 (0.386,5.321) | < 0.001 | |
|
| 0.00 | 0.144 (0.116,0.178) | 1 | |
| 0.01 | 0.369 (0.299,0.454) | 2.567 (2.300,2.865) | < 0.001 | |
| 0.05 | 0.600 (0.488,0.737) | 4.174 (3.751,4.644) | < 0.001 | |
| 0.10 | 1.471 (1.197,1.808) | 10.237 (9.204,11.357) | < 0.001 | |
| 2.00 | 6.121 (4.939,7.588) | 42.604 (37.718,48.122) | < 0.001 | |
|
| 0.00 | 0.096 (0.044,0.211) | 1 | |
| 0.01 | 0.319 (0.145,0.699) | 3.325 (2.947,3.752) | 0.004 | |
| 0.05 | 0.622 (0.284,1.362) | 6.487 (5.767,7.298) | < 0.001 | |
| 0.10 | 1.094 (0.500,2.396) | 11.41 (10.145,12.839) | < 0.001 | |
| 2.00 | 2.067 (0.944,4.528) | 21.56 (19.119,24.306) | 0.070 |
CI = confidence interval, RR = risk ratio. Control used as reference RR = 1, the predicted means were derived from generalized linear model which is the average of larvae dead in each concentration
Figure 3results of pair-wise post hoc comparison using Tukey's honestly significance tests (Tukey's HSD); similarities and differences between larvae mortality at different concentrations; A) An. gambiae; B) An. arabiensis and C) An. funestus
Figure 4percentage inhibition of pupation of different malaria vectors at different test concentration of novaluron 15 days post-treatment